The present invention relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.

Gillessen; Hubert Jean Marie Franc

Rebiere; Christian

Veijlen N.V.

Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals

The present disclosure relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular, in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.

VEIJLEN N.V.

Veijlen

The present invention relates to an in vitro diagnostic method for the determination of specific dopamine-.beta.-hydroxylase activity for the evaluation of the sympathetic nervous system function of a patient from a serum sample; which comprises the steps of: a) filtering the serum sample to substantially remove drugs and endogenous inhibitors of dopamine-.beta.-hydroxylase; b) incubating the filtered sample of step a) with a substrate of dopamine-.beta.-hydroxylase for conversion in a detectable compound; c) determining the amount of detectable compound to evaluate dopamine-.beta.-hydroxylase activity and comparing with a normal sample; whereby an amount lower than a normal sample is indicative of a reduced sympathetic nervous system function and an amount higher than a normal sample is indicative of an increased sympathetic nervous system function. A reduction in the sympathetic nervous system function is indicative of neurodegenerative, neuroendocrine, psycho-affective and cardiovascular diseases, burn-out, and chronic fatigue, and the effects of stress such as panic syndrome. An increased in the sympathetic nervous system function is indicative of the effects of stress.

burns/väsimus

Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals

Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals

Diagnostic methods and kits for the evaluation of the sympathetic nervous system function

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus